Document is current
Any future updates will be listed below
-
Authors
Kaushal, Sunjay https://orcid.org/0000-0001-7733-7320
Hare, Joshua M.
Shah, Aakash M.
Pietris, Nicholas P.
Bettencourt, Judith L.
Piller, Linda B.
Khan, Aisha
Snyder, Abigail
Boyd, Riley M.
Abdullah, Mohamed
Mishra, Rachana
Sharma, Sudhish
Slesnick, Timothy C.
Si, Ming-Sing
Chai, Paul J.
Davis, Barry R.
Lai, Dejian
Davis, Michael E.
Mahle, William T.
-
Funding
Funding for this research was provided by:
Billi and Bernie Marcus Foundation
National Heart, Lung, and Blood Institute (R01HL118491, R01HL139060-01A1, R42HL131226-01, R01HL107110, 1R01HL134558-01, 4R01HL084275-10, 5R01HL116899-04, HHSN2682016000121)
Moseley Foundation
Maryland Stem Cell Research Fund
National Cancer Institute (5R01CA136387-07)
Soffer Family Foundation
Sarr Foundation
National Institutes of Health (K08HL146351)
- License Information
-
More Information
Article History
Received: 12 January 2022
Accepted: 7 March 2022
First Online: 8 April 2022
Declarations
:
: Joshua M. Hare reports having a patent for cardiac cell-based therapy and holds equity in Vestion Inc. and maintains a professional relationship with Vestion Inc. as a consultant and member of the Board of Directors and Scientific Advisory Board. Vestion Inc. did not play a role in the design, conduct, or funding of the study. Dr. Joshua Hare is the Chief Scientific Officer, a compensated consultant and board member for Longeveron Inc. and holds equity in Longeveron. Dr. Hare is also the co-inventor of intellectual property licensed to Longeveron. Longeveron did not play a role in the design, conduct, or funding of the study. The University of Miami is an equity owner in Longeveron Inc., which has licensed intellectual property from the University of Miami. Sunjay Kaushal is a founder of Neoprogen, Inc.
